Our first cohort consisted of 186 pre‐invasive (stage 0, DCIS only) and early invasive breast cancer (IMC; invasive mammary carcinoma, stage I) patient samples, where we used an antibody that recognizes both TBX3 isoforms. This evidence concerns the gene TBX3 and invasive breast carcinoma.